Levothyroxine/Liothyronine once daily
Small molecule
Levothyroxine/Liothyronine once daily is one of 19 small molecule programs targeting Hypothyroidism. It is currently in development.
1
Indications
1
Total Trials
1
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
43 competitors in Hypothyroidism
#DrugCompanyPhaseTrials
1Synthroid
IInstitut Jerome Lejeune
Approved
Tricor
JJagotec
Approved
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Growth Hormone
PfizerApproved
L-Carnitine
IIperboreal Pharma Srl
Approved
Calcitonin
TTarsa Therapeutics, Inc.
Approved
Triiodothyronine
HHadassah Medical Organization
Approved
Levothyroxin
BBerlin-Chemie AG Menarini Group
Approved
L-Thyroxine
SShandong Provincial Hospital
Approved
Farxiga
AstraZenecaPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- UUConn Health